Waverley Pharma Inc. (TSXV:WAVE)

Waverley Pharma Statistics

Total Valuation

Waverley Pharma has a market cap or net worth of CAD 540,000. The enterprise value is 4.01 million.

Market Cap	540,000
Enterprise Value	4.01M

Important Dates

The next estimated earnings date is Wednesday, August 26, 2026.

Earnings Date	Aug 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Waverley Pharma has 54.00 million shares outstanding.

Current Share Class	54.00M
Shares Outstanding	54.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	74.90%
Owned by Institutions (%)	n/a
Float	13.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.43
PB Ratio	-0.20
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.38
EV / Sales	3.22
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.11

Current Ratio	0.11
Quick Ratio	0.02
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.50

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-20.85%
Return on Invested Capital (ROIC)	-30.76%
Return on Capital Employed (ROCE)	17.74%
Weighted Average Cost of Capital (WACC)	4.94%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.92
Inventory Turnover	2.81

Taxes

In the past 12 months, Waverley Pharma has paid 1,631 in taxes.

Income Tax	1,631
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.00% in the last 52 weeks. The beta is 1.21, so Waverley Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.21
52-Week Price Change	-60.00%
50-Day Moving Average	0.02
200-Day Moving Average	0.02
Relative Strength Index (RSI)	41.42
Average Volume (20 Days)	16,339

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Waverley Pharma had revenue of CAD 1.25 million and -628,603 in losses. Loss per share was -0.01.

Revenue	1.25M
Gross Profit	464,979
Operating Income	-452,577
Pretax Income	-626,972
Net Income	-628,603
EBITDA	-395,644
EBIT	-452,577
Loss Per Share	-0.01

Balance Sheet

The company has 68,601 in cash and 3.54 million in debt, with a net cash position of -3.47 million or -0.06 per share.

Cash & Cash Equivalents	68,601
Total Debt	3.54M
Net Cash	-3.47M
Net Cash Per Share	-0.06
Equity (Book Value)	-2.73M
Book Value Per Share	-0.05
Working Capital	-3.34M

Cash Flow

Operating Cash Flow	-514,622
Capital Expenditures	n/a
Depreciation & Amortization	56,933
Net Borrowing	440,957
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 37.34%, with operating and profit margins of -36.34% and -50.47%.

Gross Margin	37.34%
Operating Margin	-36.34%
Pretax Margin	-50.34%
Profit Margin	-50.47%
EBITDA Margin	-31.77%
EBIT Margin	-36.34%
FCF Margin	n/a

Dividends & Yields

Waverley Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-116.41%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Waverley Pharma has an Altman Z-Score of -16.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-16.3
Piotroski F-Score	2